



## Sofosbuvir-Based and Elbasvir/Grazoprevir Treatment Failures

Recommended and alternative regimens listed by evidence level and alphabetically for:

### Sofosbuvir-Based Treatment Failures, With or Without Compensated Cirrhosis<sup>a</sup>

| RECOMMENDED   | DURATION | RATING  |
|---|----------|--|
| Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) <sup>b</sup>   | 12 weeks | I, A   |
| ALTERNATIVE   | DURATION | RATING  |
| Daily fixed-dose combination of glecaprevir (300 mg)/pibrentasvir (120 mg) except for NS3/4 protease inhibitor inclusive combination DAA regimen failures <sup>c</sup> <ul style="list-style-type: none"> <li>• <b>Not</b> recommended for genotype 3 infection with sofosbuvir/NS5A inhibitor experience.</li> </ul> | 16 weeks | I, A   |

<sup>a</sup> For [decompensated cirrhosis](#), please refer to the appropriate section.

<sup>b</sup> Genotype 3: Add weight-based ribavirin if cirrhosis is present and there are no contraindications.

<sup>c</sup> This regimen is not recommended for patients with prior exposure to an NS5A inhibitor plus NS3/4 PI regimens (e.g., elbasvir/grazoprevir).

**Last update:** October 24, 2022